scholarly journals Optical Imaging in Breast Cancer Diagnosis: The Next Evolution

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Michel Herranz ◽  
Alvaro Ruibal
Keyword(s):  
Breast Cancer ◽  
Optical Imaging ◽  
Breast Imaging ◽  
Near Infrared ◽  
High Sensitivity ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Methods ◽  
Infrared Light ◽  
Western World ◽  
Positron Emission

Breast cancer is one of the most common cancers among the population of the Western world. Diagnostic methods include mammography, ultrasound, and magnetic resonance; meanwhile, nuclear medicine techniques have a secondary role, being useful in regional assessment and therapy followup. Optical imaging is a very promising imaging technique that uses near-infrared light to assess optical properties of tissues and is expected to play an important role in breast cancer detection. Optical breast imaging can be performed by intrinsic breast tissue contrast alone (hemoglobin, water, and lipid content) or with the use of exogenous fluorescent probes that target specific molecules for breast cancer. Major advantages of optical imaging are that it does not use any radioactive components, very high sensitivity, relatively inexpensive, easily accessible, and the potential to be combined in a multimodal approach with other technologies such as mammography, ultrasound, MRI, and positron emission tomography. Moreover, optical imaging agents could, potentially, be used as “theranostics,” combining the process of diagnosis and therapy.

scholarly journals Author Correction: High-sensitivity imaging of time-domain near-infrared light transducer

2021 ◽  
Author(s):  
Yuyang Gu ◽  
Zhiyong Guo ◽  
Wei Yuan ◽  
Mengya Kong ◽  
Yulai Liu ◽  
...  
Keyword(s):  
Time Domain ◽  
Near Infrared ◽  
High Sensitivity ◽  
Infrared Light ◽  
Near Infrared Light

scholarly journals Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Xiao-hong Mao ◽  
Qiang Ye ◽  
Guo-bing Zhang ◽  
Jin-ying Jiang ◽  
Hong-ying Zhao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
High Sensitivity ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Value ◽  
Methylation Pattern ◽  
Clinical Value ◽  
Roc Curve Analysis ◽  
Differentially Methylated Genes ◽  
Sensitivity Specificity

Abstract Background Aberrant DNA methylation is significantly associated with breast cancer. Methods In this study, we aimed to determine novel methylation biomarkers using a bioinformatics analysis approach that could have clinical value for breast cancer diagnosis and prognosis. Firstly, differentially methylated DNA patterns were detected in breast cancer samples by comparing publicly available datasets (GSE72245 and GSE88883). Methylation levels in 7 selected methylation biomarkers were also estimated using the online tool UALCAN. Next, we evaluated the diagnostic value of these selected biomarkers in two independent cohorts, as well as in two mixed cohorts, through ROC curve analysis. Finally, prognostic value of the selected methylation biomarkers was evaluated breast cancer by the Kaplan-Meier plot analysis. Results In this study, a total of 23 significant differentially methylated sites, corresponding to 9 different genes, were identified in breast cancer datasets. Among the 9 identified genes, ADCY4, CPXM1, DNM3, GNG4, MAST1, mir129-2, PRDM14, and ZNF177 were hypermethylated. Importantly, individual value of each selected methylation gene was greater than 0.9, whereas predictive value for all genes combined was 0.9998. We also found the AUC for the combined signature of 7 genes (ADCY4, CPXM1, DNM3, GNG4, MAST1, PRDM14, ZNF177) was 0.9998 [95% CI 0.9994–1], and the AUC for the combined signature of 3 genes (MAST1, PRDM14, and ZNF177) was 0.9991 [95% CI 0.9976–1]. Results from additional validation analyses showed that MAST1, PRDM14, and ZNF177 had high sensitivity, specificity, and accuracy for breast cancer diagnosis. Lastly, patient survival analysis revealed that high expression of ADCY4, CPXM1, DNM3, PRDM14, PRKCB, and ZNF177 were significantly associated with better overall survival. Conclusions Methylation pattern of MAST1, PRDM14, and ZNF177 may represent new diagnostic biomarkers for breast cancer, while methylation of ADCY4, CPXM1, DNM3, PRDM14, PRKCB, and ZNF177 may hold prognostic potential for breast cancer.

Breast malignancy

2021 ◽  
pp. 1025-1052
Author(s):  
Kieran Horgan ◽  
Barbara Dall ◽  
Rebecca Millican-Slater ◽  
Russell Bramhall ◽  
Fiona MacNeill ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United Kingdom ◽  
Cancer Diagnosis ◽  
Invasive Breast Cancer ◽  
Breast Cancer Diagnosis ◽  
Developed Countries ◽  
Western World ◽  
Breast Malignancy ◽  
The United Kingdom

Breast cancer is the commonest cancer to affect women in developed countries and is increasing in frequency in the Western world. Approximately 50,000 women and 400 men are diagnosed with breast cancer in the United Kingdom each year. Eighty per cent of these individuals will survive for at least 5 years after diagnosis. In 2012, 11,762 women died of breast cancer in the United Kingdom. Age-standardized rates of new invasive breast cancer diagnosis have increased from 75 to 126 per 100,000 population in the United Kingdom between 1977 and 2010.

scholarly journals Handheld diffuse optical breast scanner probe for cross-sectional imaging of breast tissue

2019 ◽  
Vol 12 (02) ◽  
pp. 1950008 ◽  
Author(s):  
Majid Shokoufi ◽  
Farid Golnaraghi
Keyword(s):  
Breast Cancer ◽  
Breast Imaging ◽  
Breast Tissue ◽  
Reconstruction Algorithm ◽  
Breast Cancer Diagnosis ◽  
Array Detector ◽  
Light Sources ◽  
Compact Structure ◽  
Cross Sectional

Diffuse optical spectroscopy is a relatively new, noninvasive and nonionizing technique for breast cancer diagnosis. In the present study, we have introduced a novel handheld diffuse optical breast scan (DOB-Scan) probe to measure optical properties of the breast in vivo and create functional and compositional images of the tissue. In addition, the probe gives more information about breast tissue’s constituents, which helps distinguish a healthy and cancerous tissue. Two symmetrical light sources, each including four different wavelengths, are used to illuminate the breast tissue. A high-resolution linear array detector measures the intensity of the back-scattered photons at different radial destinations from the illumination sources on the surface of the breast tissue, and a unique image reconstruction algorithm is used to create four cross-sectional images for four different wavelengths. Different from fiber optic-based illumination techniques, the proposed method in this paper integrates multi-wavelength light-emitting diodes to act as pencil beam sources into a scattering medium like breast tissue. This unique design and its compact structure reduce the complexity, size and cost of a potential probe. Although the introduced technique miniaturizes the probe, this study points to the reliability of this technique in the phantom study and clinical breast imaging. We have received ethical approval to test the DOB-Scan probe on patients and we are currently testing the DOB-Scan probe on subjects who are diagnosed with breast cancer.

scholarly journals Photobiomodulation for Alzheimer’s Disease: Has the Light Dawned?

Photonics ◽  
2019 ◽  
Vol 6 (3) ◽  
pp. 77 ◽  
Author(s):  
Michael Hamblin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Near Infrared ◽  
Infrared Light ◽  
Western World ◽  
Diverse Range ◽  
Non Invasive ◽  
Dementia Patients ◽  
Relieve Pain

Next to cancer, Alzheimer’s disease (AD) and dementia is probably the most worrying health problem facing the Western world today. A large number of clinical trials have failed to show any benefit of the tested drugs in stabilizing or reversing the steady decline in cognitive function that is suffered by dementia patients. Although the pathological features of AD consisting of beta-amyloid plaques and tau tangles are well established, considerable debate exists concerning the genetic or lifestyle factors that predispose individuals to developing dementia. Photobiomodulation (PBM) describes the therapeutic use of red or near-infrared light to stimulate healing, relieve pain and inflammation, and prevent tissue from dying. In recent years PBM has been applied for a diverse range of brain disorders, frequently applied in a non-invasive manner by shining light on the head (transcranial PBM). The present review discusses the mechanisms of action of tPBM in the brain, and summarizes studies that have used tPBM to treat animal models of AD. The results of a limited number of clinical trials that have used tPBM to treat patients with AD and dementia are discussed.

Targeted gold nanoshelled hybrid nanocapsules encapsulating doxorubicin for bimodal imaging and near-infrared triggered synergistic therapy of Her2-positve breast cancer

2020 ◽  
Vol 35 (3) ◽  
pp. 430-445
Author(s):  
Qi Dong ◽  
Caifeng Wan ◽  
Hong Yang ◽  
Dongdong Zheng ◽  
Li Xu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Near Infrared ◽  
Average Diameter ◽  
Infrared Light ◽  
Resonance Imaging ◽  
Her2 Positive ◽  
Bimodal Imaging

A multifunctional targeted nanoplatform combining photothermal therapy and chemotherapy has emerged as a promising strategy for comprehensive therapies of breast cancer. In this study, we constructed human epidermal growth factor receptor 2 (Her2)-targeted gold nanoshelled poly(lactic- co-glycolic acid) hybrid nanocapsules encapsulating perfluorooctyl bromide, superparamagnetic iron oxide nanoparticles, and doxorubicin (Her2-GPDH nanocapsules) as theranostic agent for bimodal ultrasound/magnetic resonance imaging and synergistic photothermal-chemotherapy of Her2-postive breast cancer cells. Her2–GPDH nanocomposites possessed well-defined spherical morphology, and the average diameter was about 296 nm with good dispersion. Targeting assays demonstrated that Her2–GPDH nanocapsules exhibited higher targeting binding to Her2-positive SKBR3 cells than Her2-negative MDA-MB-231cells. The encapsulation efficiency and the loading content of doxorubicin in Her2–GPDH nanocapsules were 39 ± 1.45% and 3.8 ± 0.52%, respectively, and the agent exhibited pH-responsive and near-infrared light-triggered stepwise release behavior of doxorubicin. In vitro, the agent had potential to serve as feasible candidate for ultrasound imaging and T2-weighted magnetic resonance imaging with a relatively high relaxivity. Cell experiments confirmed that the agent had significant photothermal cytotoxicity on SKBR3 cells, and the combined photothermal–chemotherapy could significantly enhance the anti-tumor effect. In summary, the present Her2–GPDH nanocapsules, a novel multifunctional nanoplatform, will offer a new way for early bimodal molecular-level diagnosis and synergistic treatment of Her2-positve breast cancer.

Sign in / Sign up

Export Citation Format

Share Document